Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Outpacing Cancer

In the late 1990s the drug gefitinib became a new tool in treating the most common type of lung cancer, called non–small cell lung cancer. But doctors found that even with continued gefitinib treatment, some patients experienced a cancer relapse within a year. For the past several years, researchers have been working to uncover why these patients lost sensitivity to gefitinib and seeking how to overcome resistance to the drug. Kirsten Dorans reports on the strategies scientists are developing to outpace continually evolving cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Druker, B.J. et al. Blood 94 (Suppl.), 368a (1999).

    Google Scholar 

  2. Sawyers, C.L. N. Engl. J. Med. 340, 1330–1340 (1999).

    Article  CAS  Google Scholar 

  3. Shah, N.P. et al. Cancer Cell 2, 117–125 (2002).

    Article  CAS  Google Scholar 

  4. Talpaz, M. et al. N. Engl. J. Med. 354, 2531–2541 (2006).

    Article  CAS  Google Scholar 

  5. Kantarjian, H. et al. N. Engl. J. Med. 354, 2542–2551 (2006).

    Article  Google Scholar 

  6. Arteaga, C.L. Exp. Cell Res. 284, 122–130 (2003).

    Article  CAS  Google Scholar 

  7. Pao, W. et al. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).

    Article  CAS  Google Scholar 

  8. Lynch, T.J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).

    Article  CAS  Google Scholar 

  9. Paez, J.G. et al. Science 304, 1497–1500 (2004).

    Article  CAS  Google Scholar 

  10. Pao, W. et al. PLoS Med. 2, e17 (2005).

    Article  Google Scholar 

  11. Kobayashi, S. et al. N. Engl. J. Med. 352, 786–792 (2005).

    Article  CAS  Google Scholar 

  12. Pao, W. et al. Proc. Natl. Acad. Sci. USA 2, e73 (2005).

    Google Scholar 

  13. Costa, D.B. et al. PLoS Med. 4, 1669–1679 (2007).

    Article  CAS  Google Scholar 

  14. Balak, M.N. et al. Clin. Cancer Res. 12, 6494–6501 (2006).

    Article  CAS  Google Scholar 

  15. Bean, J. et al. Clin. Cancer Res. 14, 7519–7525 (2008).

    Article  CAS  Google Scholar 

  16. Bell, D.W. et al. Nat. Genet. 12, 1315–1316 (2005).

    Article  Google Scholar 

  17. Yun, C.H. et al. Proc. Natl. Acad. Sci. USA 105, 2070–2075 (2008).

    Article  CAS  Google Scholar 

  18. Engelman, J.A. et al. Science 316, 1039–1043 (2007).

    Article  CAS  Google Scholar 

  19. Bean, J. et al. Proc. Natl. Acad. Sci. USA 104, 20932–20937 (2007).

    Article  CAS  Google Scholar 

  20. Carter, T.A. et al. Proc. Natl. Acad. Sci. USA 102, 11011–11016 (2005).

    Article  CAS  Google Scholar 

  21. Maheswaran, S. et al. N. Engl. J. Med. 359, 366–377 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dorans, K. Outpacing Cancer. Nat Med 15, 718–722 (2009). https://doi.org/10.1038/nm0709-718

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0709-718

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing